Tau and Aβ have emerged as key targets for AD therapy research because of the typical histopathological features of AD, which include abnormal fibrillar deposits (plaques) of Aβ peptide and NFTs of tau protein [47,48]. The gene discussed is MAPT; the disease is Alzheimer disease.